Here are relevant reports on : central-nervous-system-drug-delivery-market
-
Electronic Drug Delivery Systems Market by Type (Electronic Wearable Infusion Pump, Autoinjectors, Injection Pens, Electronic Inhalers), Indication (Diabetes, Multiple Sclerosis, Cardiovascular Disease, Asthma & COPD) - Global Forecast to 2024
The electronic drug delivery system market is expected to grow from USD 7.8 billion in 2019 to USD 11.9 billion by 2024, at a compound annual growth rate (CAGR) of 8.7%. during the forecast period.The prominent players in the electronic drug delivery systems market are Insulet Corporation (US), Bayer AG (Germany), Medtronic (Ireland), Novo Nordisk A/S (Denmark), Companion Medical (US), F.Hoffmann-La Roche Ltd (Switzerland), United Therapeutics Corporation (US), AstraZeneca (UK), Tandem Diabetes Care (US), Merck Group (Germany), and Amgen (US).
- Published: October 2019
- Price: $ 4950
- TOC Available:
-
Europe Pharmaceutical Drug Delivery Market By Route of Administration [Oral (Tablet, Capsule), Injector, Topical (Cream, Transdermal Patch), Transmucosal, Nasal], Application [Cancer, Diabetes], Care Setting [Hospital, Homecare]-Forecast to 2031
Europe Pharmaceutical Drug Delivery market, valued at US$501.6 million in 2025, stood at US$519.6 million in 2026 and is projected to advance at a resilient CAGR of 6.2% from 2026 to 2031, culminating in a forecasted valuation of US$703.2 million by the end of the period. The major trends in this market are self-administration, technology-driven drug delivery, sustainable drug delivery, and drug device combinations.
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Global Forecast to 2021
The global pulmonary drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period. Growth in this market is mainly driven by increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers and increasing incidence of respiratory diseases such as COPD, asthma, and cystic fibrosis. Emerging markets such as India, China, & Japan and growth in online marketing channels are expected to offer lucrative growth opportunities for market players in the coming years. On the other hand, factors such as regulatory issues and pricing pressures are the major factors restraining market growth.
- Published: February 2017
- Price: $ 4950
- TOC Available:
-
Live Cell Encapsulation Market by Technique (Dripping (Simple, Electrostatic), Coaxial Airflow, Liquid Jet), Polymer (Alginate, Chitosan, Silica, Cellulose Sulfate), Application (Probiotics, Transplant, Drug Delivery, Research) - Forecast to 2024
The live cell encapsulation market is projected to grow to USD 303 million by 2024 from USD 250 million in 2018, at a CAGR of 3.2% during the forecast period. Growth in the live cell encapsulation market is primarily driven by factors such as the increasing public-private investments to support product development, increasing research to establish the clinical efficacy of cell encapsulation technologies, and rising public awareness related to the clinical role of encapsulated cells in disease management. BioTime, Inc. (US), Viacyte, Inc. (US), and Living Cell Technologies Ltd. (Australia) were the top three players in the live cell encapsulation market. Other prominent players operating in this market include Sigilon Therapeutics, Inc. (US), Evonik Industries (Germany), BÜCHI Labortechnik AG (Germany), Blacktrace Holdings Ltd (UK), and Sernova Corporation (Canada), among others. Furthermore, the key players in the developmental pipeline products in this market include Neurotech Pharmaceuticals, Inc. (US), Gloriana Therapeutics (US), Kadimastem (Israel), Beta-O2 Technologies, Inc. (Israel), Defymed (France), and Altucell, Inc. (US), among others.
- Published: April 2019
- Price: $ 4950
- TOC Available:
-
Global Albumin Market, by Product (Human Serum Albumin, Bovine Albumin, Recombinant Serum Albumin) by Application (Therapeutic, Drug Delivery, Culture Media, Vaccine Ingredient) by Region - Forecast to 2022
The global albumin market is projected to grow at a CAGR of around 6% during the forecast period (2017-2022). Factors such as the high demand of albumin in R&D activities, rising non-therapeutic application of albumin, development of plant based albumin, rising production of immunoglobulins, and rise in plasma collection are driving the market. However, the stringent regulations, limited reimbursement, and irrational uses and adverse effects associated with albumin are the factors restraining the growth of this market.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Bioresorbable Polymers Market by Type (Polylactic Acid (PLA), Polyglycolic Acid (PGA), Polylactic-co-glycolic acid (PLGA), Polycaprolactone) PCL), Application (Orthopedic Devices, Drug Delivery), and Region - Global Forecast to 2029
The bioresorbable polymers market is expected to grow from USD 500.0 million in 2024 to USD 867.2 million by 2029, at a CAGR of 11.6% during the forecast period. The key players profiled in the report include Corbion (Netherlands), Evonik Industries AG (Germany), Foster Corporation (US), KLS Martin Group (Germany), DSM Biomedical (US), Ashland Global Holdings Inc. (US), Zeus Company LLC (US), Seqens (France), Reva Medical, LLC (US), and Poly-Med Incorporated (US).
- Published: November 2024
- Price: $ 4950
- TOC Available:
-
Europe Injectable Drug Delivery Market by Product (Device, Self Injection, Formulation, Solution, Emulsions), Formulation Packaging (Ampoules, Bottles), Therapeutic Application (Obesity, Diabetes, Cancer, Psoriasis), Usage Pattern - Forecast to 2031
The Europe injectable drug delivery market is projected to reach USD 259.49 billion by 2031 from USD 178.87 billion in 2026, at a CAGR of 7.7% during the forecast period. The prominent players in the injectable drug delivery market in Europe are BD (US), Baxter (US), Gerresheimer AG (Germany), SCHOTT Pharma (Germany), West Pharmaceutical Services, Inc. (US), Pfizer Inc. (US), Sanofi (France), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), and Johnson & Johnson (US), among others.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Injectable Drug Delivery Market by Product (Device, Autoinjectors, Formulation, Suspensions, Nanoparticles), Site of Administration (Dermal, Organ), Formulation Packaging (Ampoules, Vials), Usage Pattern (Curative, Immunization) - Forecast to 2031
The Asia Pacific injectable drug delivery market is projected to reach USD 282.22 billion by 2031 from USD 176.96 billion in 2026, at a CAGR of 9.8% during the forecast period. The prominent players in the Asia Pacific injectable drug delivery market are BD (US), Terumo Corporation (Japan), Nipro (Japan), Hindustan Syringes & Medical Devices Ltd (India), B. Braun SE (Germany), Pfizer Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Novo Nordisk A/S (Denmark), and Novartis AG (Switzerland), among others.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Laboratory Information System (LIS) Market by Product (Standalone, Integrated), Component (Services, Software), Delivery Mode (On-premise & Cloud-based), End User (Hospital Laboratories, Independent Laboratories, POLs) and Region - Global Forecast to 2028
The global laboratory information system market, valued at US$2.0 billion in 2022, stood at US$2.4 billion in 2023 and is projected to advance at a resilient CAGR of 10.8% from 2023 to 2028, culminating in a forecasted valuation of US$4.0 billion by the end of the period. The expansion of molecular diagnostic techniques, including genomics and personalized medicine, and the need for automation and robotics in laboratories primarily drive the market growth.
- Published: July 2023
- Price: $ 4950
- TOC Available:
-
Emergency Department Information System Market by Delivery Mode (On-Premise, Software as a Service), Software Type (Best-Of-Breed, Enterprise Solutions), Application (CPOE, Patient Tracking & Triage), End User Global Forecast to 2019
The global emergency department information system (EDIS) market was valued at $312.68 million in 2014 and poised to grow at a CAGR of 15.24% between 2012 and 2019, to reach $635.50 million in 2019. The rapid increase in healthcare expenditure, increasing use of data-driven technologies, implementation of the HITECH Act, and rise in aging population will be the most important growth drivers for this market in the forecast period (20122019).
- Published: November 2014
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
